Eric Wexler, M.D., Ph.D., Modern Brains PsychiatryEric Wexler, M.D., Ph.D.Diplomate, American Board of Psychiatry & Neurology

Special Topics

References

Full reference list for Psychosis and Regression in Down Syndrome. For a recent peer-reviewed overview, see the Santoro et al. (2024) review (PDF).

Back to the article
  1. Anand, V., Shukla, G., Gupta, N., et al. (2021). Association of sleep apnea with development and behavior in Down syndrome: A prospective clinical and polysomnographic study. Pediatric Neurology, 116, 7-13. https://doi.org/10.1016/j.pediatrneurol.2020.10.007
  2. Appiani, F. J., Duarte, J. M., Sauré, M., et al. (2023). Catatonia and delirium: Assessment of comorbidity, prevalence, and therapeutic response in medically ill inpatients from a university hospital. Journal of Clinical Psychopharmacology, 43(1), 55-59. https://doi.org/10.1097/JCP.0000000000001621
  3. Araya, P., Waugh, K. A., Sullivan, K. D., et al. (2019). Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proceedings of the National Academy of Sciences of the United States of America, 116(48), 24231-24241. https://doi.org/10.1073/pnas.1908129116
  4. Arranz, J., Lantero-Rodríguez, J., Braun-Wohlfahrt, L. S., et al. (2026). CSF and plasma tau biomarkers in the Down syndrome-Alzheimer's disease continuum. EBioMedicine, 130, 106370. https://doi.org/10.1016/j.ebiom.2026.106370
  5. Ayub, M., Saeed, K., Munshi, T. A., & Naeem, F. (2015). Clozapine for psychotic disorders in adults with intellectual disabilities. The Cochrane Database of Systematic Reviews, (9), CD010625. https://doi.org/10.1002/14651858.CD010625.pub2
  6. Baksh, R. A., Pape, S. E., Chan, L. F., et al. (2023). Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: A population-based cohort study using electronic health records. The Lancet Public Health, 8(6), e453-e462. https://doi.org/10.1016/S2468-2667(23)00057-9
  7. Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016). Dementia in Down's syndrome. The Lancet Neurology, 15(6), 622-636. https://doi.org/10.1016/S1474-4422(16)00063-6
  8. Barišić, A., Ravančić, M. E., Majstorivić, D., & Vraneković, J. (2023). Micronutrient status in children and adolescents with Down syndrome: Systematic review and meta-analysis. Journal of Intellectual Disability Research: JIDR, 67(8), 701-719. https://doi.org/10.1111/jir.13042
  9. Beresford-Webb, J. A., Mak, E., Grigorova, M., et al. (2021). Establishing diagnostic thresholds for Alzheimer's disease in adults with Down syndrome: The Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities (CAMDEX-DS). BJPsych Open, 7(3), e79. https://doi.org/10.1192/bjo.2021.36
  10. Betoni, N. J., Okamoto, C. M., Lott, I. T., & Hom, C. L. (2025). Cognitive and behavioural associations of visual and hearing impairments across the lifespan in people with Down syndrome, a scoping review. Journal of Intellectual Disability Research: JIDR. https://doi.org/10.1111/jir.13248
  11. Boelen, R., & de Vries, T. (2021). Clinical characteristics of paediatric Hashimoto's encephalopathy. European Journal of Paediatric Neurology, 32, 122-127. https://doi.org/10.1016/j.ejpn.2021.04.006
  12. Bonne, S., Iftimovici, A., Mircher, C., et al. (2023). Down syndrome regression disorder, a case series: Clinical characterization and therapeutic approaches. Frontiers in Neuroscience, 17, 1126973. https://doi.org/10.3389/fnins.2023.1126973
  13. Brodtmann, A. (2009). Hashimoto encephalopathy and Down syndrome. Archives of Neurology, 66(5), 663-666. https://doi.org/10.1001/archneurol.2009.45
  14. Bull, M. J. (2020). Down syndrome. The New England Journal of Medicine, 382(24), 2344-2352. https://doi.org/10.1056/NEJMra1706537
  15. Bull, M. J., Trotter, T., Santoro, S. L., et al. (2022). Health supervision for children and adolescents with Down syndrome. Pediatrics, 149(5), e2022057010. https://doi.org/10.1542/peds.2022-057010
  16. Capone, G. T., Goyal, P., Grados, M., Smith, B., & Kammann, H. (2008). Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study. Journal of Developmental and Behavioral Pediatrics: JDBP, 29(2), 106-116. https://doi.org/10.1097/DBP.0b013e318165c100
  17. Charlot, L. R., Doerfler, L. A., & McLaren, J. L. (2020). Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities. Journal of Intellectual Disability Research: JIDR, 64(11), 852-863. https://doi.org/10.1111/jir.12777
  18. Ciciora, S. L., Manickam, K., & Saps, M. (2023). Disorders of gut-brain interaction in a national cohort of children with Down syndrome. Journal of Neurogastroenterology and Motility, 29(1), 94-101. https://doi.org/10.5056/jnm22055
  19. Collacott, R. A., Cooper, S. A., & McGrother, C. (1992). Differential rates of psychiatric disorders in adults with Down's syndrome compared with other mentally handicapped adults. The British Journal of Psychiatry: The Journal of Mental Science, 161, 671-674. https://doi.org/10.1192/bjp.161.5.671
  20. Connors, M. H., Sachdev, P. S., Colebatch, J. G., et al. (2024). Case report: Down syndrome regression disorder, catatonia, and psychiatric and immunomodulatory interventions. Frontiers in Psychiatry, 15, 1416736. https://doi.org/10.3389/fpsyt.2024.1416736
  21. Cooper, S. A., Melville, C. A., & Einfeld, S. L. (2003). Psychiatric diagnosis, intellectual disabilities and diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC-LD). Journal of Intellectual Disability Research: JIDR, 47(S1), 3-15. https://doi.org/10.1046/j.1365-2788.47.s1.2.x
  22. Corniello, C., Dono, F., Evangelista, G., et al. (2024). Diagnosis and treatment of status epilepticus in Down syndrome (DS): A case report and systematic literature review. Seizure, 114, 90-95. https://doi.org/10.1016/j.seizure.2023.11.009
  23. Deb, S., Hare, M., Prior, L., & Bhaumik, S. (2007). Dementia screening questionnaire for individuals with intellectual disabilities. The British Journal of Psychiatry: The Journal of Mental Science, 190, 440-444. https://doi.org/10.1192/bjp.bp.106.024984
  24. Deutsch, S. I., & Burket, J. A. (2021). Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 104, 110017. https://doi.org/10.1016/j.pnpbp.2020.110017
  25. Einfeld, S. L., Piccinin, A. M., Mackinnon, A., et al. (2006). Psychopathology in young people with intellectual disability. JAMA, 296(16), 1981-1989. https://doi.org/10.1001/jama.296.16.1981
  26. Espinoza, R. T., & Kellner, C. H. (2022). Electroconvulsive therapy. The New England Journal of Medicine, 386(7), 667-672. https://doi.org/10.1056/NEJMra2034954
  27. Ferriero, D. M., Fullerton, H. J., Bernard, T. J., et al. (2019). Management of stroke in neonates and children: A scientific statement from the American Heart Association/American Stroke Association. Stroke, 50(3), e51-e96. https://doi.org/10.1161/STR.0000000000000183
  28. Food and Drug Administration. FDA Orange Book.
  29. Forte, L., Bianco, A., & Bertelli, M. O. (2026). Instrumental assessment of psychotic disorders in intellectual developmental disorders and autism with cognitive or major communication issues. Current Opinion in Psychiatry, 39(2), 83-90. https://doi.org/10.1097/YCO.0000000000001075
  30. Fortea, J., Vilaplana, E., Carmona-Iragui, M., et al. (2020). Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. The Lancet, 395(10242), 1988-1997. https://doi.org/10.1016/S0140-6736(20)30689-9
  31. Fortea, J., Zaman, S. H., Hartley, S., et al. (2021). Alzheimer's disease associated with Down syndrome: A genetic form of dementia. The Lancet Neurology, 20(11), 930-942. https://doi.org/10.1016/S1474-4422(21)00245-3
  32. Fotheringham, J. B., & Thompson, F. (1994). Case report of a person with Down's syndrome and multiple personality disorder. Canadian Journal of Psychiatry, 39(2), 116-119. https://doi.org/10.1177/070674379403900210
  33. Ghaziuddin, N., Nassiri, A., & Miles, J. H. (2015). Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatric Disease and Treatment, 11, 941-949. https://doi.org/10.2147/NDT.S77307
  34. Glasson, E. J., Buckley, N., Chen, W., et al. (2020). Systematic review and meta-analysis: Mental health in children with neurogenetic disorders associated with intellectual disability. Journal of the American Academy of Child and Adolescent Psychiatry, 59(9), 1036-1048. https://doi.org/10.1016/j.jaac.2020.01.006
  35. Grotteschi, N., Rochat, M. J., Pollarini, V., et al. (2025). Neurological findings in a cohort of adults with Down syndrome. Neurological Sciences. https://doi.org/10.1007/s10072-025-08195-7
  36. Hamad, A. P., Ferrari-Marinho, T., Caboclo, L. O., Thomé, U., & Fernandes, R. M. F. (2020). Nonconvulsive status epilepticus in epileptic encephalopathies in childhood. Seizure, 80, 212-220. https://doi.org/10.1016/j.seizure.2020.06.024
  37. Hart, S. J., Worley, G., Kishnani, P. S., & Van Mater, H. (2021). Case report: Improvement following immunotherapy in an individual with seronegative Down syndrome disintegrative disorder. Frontiers in Neurology, 12, 621637. https://doi.org/10.3389/fneur.2021.621637
  38. Hasan, S., Desarkar, P., Lunsky, Y., & Thakur, A. (2025). Catatonia in autistic adults in a tertiary inpatient and outpatient neurodevelopmental service: A retrospective review. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-025-06837-5
  39. Heckers, S., & Walther, S. (2023). Catatonia. The New England Journal of Medicine, 389(19), 1797-1802. https://doi.org/10.1056/NEJMra2116304
  40. Hua, L. L. (2021). Collaborative care in the identification and management of psychosis in adolescents and young adults. Pediatrics, 147(6), e2021051486. https://doi.org/10.1542/peds.2021-051486
  41. Huber, H., Arranz, J., Arslan, B., et al. (2025). Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome. Nature Communications, 16(1), 9900. https://doi.org/10.1038/s41467-025-65882-x
  42. Jafarpour, S., Banerjee, A. K., Khoshnood, M. M., et al. (2024). De novo variants in immune regulatory genes in Down syndrome regression disorder. Journal of Neurology, 271(8), 5567-5576. https://doi.org/10.1007/s00415-024-12521-y
  43. Janelidze, S., Collij, L. E., Mattsson-Carlgren, N., et al. (2025). Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: A longitudinal cohort study. The Lancet Neurology, 24(7), 591-600. https://doi.org/10.1016/S1474-4422(25)00158-9
  44. Kainth, D. S., Chaudhry, S. A., Kainth, H. S., Suri, F. K., & Qureshi, A. I. (2013). Prevalence and characteristics of concurrent Down syndrome in patients with moyamoya disease. Neurosurgery, 72(2), 210-215. https://doi.org/10.1227/NEU.0b013e31827b9beb
  45. Kaur, S., Silver, G., Samuels, S., et al. (2020). Delirium and developmental disability: Improving specificity of a pediatric delirium screen. Pediatric Critical Care Medicine, 21(5), 409-414. https://doi.org/10.1097/PCC.0000000000002248
  46. Kelley, B. J., Bailey, K. J., & Hubregsen, J. J. (2025). Clinical response to electroconvulsive therapy in a young adult with Down syndrome regression disorder. The Journal of ECT, 41(2), e18-e20. https://doi.org/10.1097/YCT.0000000000001093
  47. Komatsu, H., Nishimura, A., Okano, S., et al. (1992). Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification. Brain & Development, 14(6), 400-403. https://doi.org/10.1016/s0387-7604(12)80348-2
  48. Kong, X. F., Worley, L., Rinchai, D., et al. (2020). Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. Journal of Clinical Immunology, 40(6), 807-819. https://doi.org/10.1007/s10875-020-00803-9
  49. Lautarescu, B. A., Holland, A. J., & Zaman, S. H. (2017). The early presentation of dementia in people with Down syndrome: A systematic review of longitudinal studies. Neuropsychology Review, 27(1), 31-45. https://doi.org/10.1007/s11065-017-9341-9
  50. Lichtor, S. A., Berk, R., Gimler, K., & Siegel, M. (2026). Communicating constipation: Differential diagnosis of agitation in autism at a pediatric hospital. Pediatrics, 157(5), e2025073672. https://doi.org/10.1542/peds.2025-073672
  51. Liu, E., Wolter-Warmerdam, K., Marmolejo, J., et al. (2020). Routine screening for celiac disease in children with Down syndrome improves case finding. Journal of Pediatric Gastroenterology and Nutrition, 71(2), 252-256. https://doi.org/10.1097/MPG.0000000000002742
  52. Malle, L., Patel, R. S., Martin-Fernandez, M., et al. (2023). Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells. Nature, 615(7951), 305-314. https://doi.org/10.1038/s41586-023-05736-y
  53. Mannion, A., Neil, N., Fiani, T., et al. (2024). An investigation of sleep problems, gastrointestinal symptoms, comorbid psychopathology and challenging behavior in children and adolescents with Down syndrome. Research in Developmental Disabilities, 151, 104788. https://doi.org/10.1016/j.ridd.2024.104788
  54. Mantry, D., Cooper, S. A., Smiley, E., et al. (2008). The prevalence and incidence of mental ill-health in adults with Down syndrome. Journal of Intellectual Disability Research: JIDR, 52(2), 141-155. https://doi.org/10.1111/j.1365-2788.2007.00985.x
  55. Matsui Yamaguchi, M. Y., Silva Nunes, C. N., de Freitas Júnior, W. R., et al. (2026). Prevalence and severity of sleep-disordered breathing in individuals with Down syndrome using a portable home-based diagnostic device: A pilot study. Scientific Reports, 16(1), 22905. https://doi.org/10.1038/s41598-026-46328-w
  56. Melville, C. A. (2003). A critique of the diagnostic criteria for psychiatric disorders for use with adults with learning disabilities/mental retardation (DC-LD) chapter on non-affective psychotic disorders. Journal of Intellectual Disability Research: JIDR, 47(S1), 16-25. https://doi.org/10.1046/j.1365-2788.47.s1.12.x
  57. Miles, J. H., Takahashi, N., Muckerman, J., Nowell, K. P., & Ithman, M. (2019). Catatonia in Down syndrome: Systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatric Disease and Treatment, 15, 2723-2741. https://doi.org/10.2147/NDT.S210613
  58. Minamisawa, Y., Sato, M., Saito, Y., et al. (2023). Case report: Evolution of catatonic mutism and psychotic symptoms in an adolescent with Down syndrome: Transition from Down syndrome disintegrative disorder to anti-N-methyl-D-aspartate receptor encephalitis. Frontiers in Neurology, 14, 1200541. https://doi.org/10.3389/fneur.2023.1200541
  59. Morgan, V. A., Leonard, H., Bourke, J., & Jablensky, A. (2008). Intellectual disability co-occurring with schizophrenia and other psychiatric illness: Population-based study. The British Journal of Psychiatry: The Journal of Mental Science, 193(5), 364-372. https://doi.org/10.1192/bjp.bp.107.044461
  60. Moss, S., Prosser, H., & Goldberg, D. (1996). Validity of the schizophrenia diagnosis of the Psychiatric Assessment Schedule for Adults with Developmental Disability (PAS-ADD). The British Journal of Psychiatry: The Journal of Mental Science, 168(3), 359-367. https://doi.org/10.1192/bjp.168.3.359
  61. Musaeus, C. S., Salem, L. C., Sabers, A., Kjaer, T. W., & Waldemar, G. (2019). Associations between electroencephalography power and Alzheimer's disease in persons with Down syndrome. Journal of Intellectual Disability Research: JIDR, 63(9), 1151-1157. https://doi.org/10.1111/jir.12627
  62. Nordstrøm, M., Retterstøl, K., Hope, S., & Kolset, S. O. (2020). Nutritional challenges in children and adolescents with Down syndrome. The Lancet Child & Adolescent Health, 4(6), 455-464. https://doi.org/10.1016/S2352-4642(19)30400-6
  63. Ortega, M. D. C., Ortuño, F., & Real de Asúa, D. (2026). Psychosocial stressors prior to Down syndrome regression disorder: Findings from two referral clinics. Frontiers in Psychiatry, 17, 1799799. https://doi.org/10.3389/fpsyt.2026.1799799
  64. Palumbo, M. L., & McDougle, C. J. (2018). Pharmacotherapy of Down syndrome. Expert Opinion on Pharmacotherapy, 19(17), 1875-1889. https://doi.org/10.1080/14656566.2018.1529167
  65. Patel, H., & McGuirk, R. (2025). Vitamin B12 deficiency: Common questions and answers. American Family Physician, 112(3), 294-300.
  66. Prout, K. K., Kitchen, J., Tobler, L., & Nyp, S. S. (2025). Self-talk in a patient with Down syndrome: When is it a concern? Journal of Developmental and Behavioral Pediatrics: JDBP, 46(3), e326-e328. https://doi.org/10.1097/DBP.0000000000001359
  67. Rachubinski, A. L., Wallace, E., Gurnee, E., et al. (2024). JAK inhibition decreases the autoimmune burden in Down syndrome. eLife, 13, RP99323. https://doi.org/10.7554/eLife.99323
  68. Rafii, M. S., Schlachetzki, Z., Barroeta, I., et al. (2025). Down syndrome and Alzheimer's disease: Insights into biomarkers, clinical symptoms, and pathology. The Lancet Neurology, 24(9), 753-762. https://doi.org/10.1016/S1474-4422(25)00237-6
  69. Ray, W. A., Fuchs, D. C., Olfson, M., et al. (2024). Incidence of neuroleptic malignant syndrome during antipsychotic treatment in children and youth: A national cohort study. Journal of Child and Adolescent Psychopharmacology, 34(9), 397-406. https://doi.org/10.1089/cap.2024.0047
  70. Rodriguez, L., Ambartsumyan, L., Baumgartner, K., et al. (2026). American Gastroenterological Association-North American Society for Pediatric Gastroenterology, Hepatology and Nutrition pediatric functional constipation clinical care pathway. Clinical Gastroenterology and Hepatology, S1542-3565(26)00159-X. https://doi.org/10.1016/j.cgh.2026.03.003
  71. Roizen, N. J., & Patterson, D. (2003). Down's syndrome. The Lancet, 361(9365), 1281-1289. https://doi.org/10.1016/S0140-6736(03)12987-X
  72. Rosso, M., Fremion, E., Santoro, S. L., et al. (2020). Down syndrome disintegrative disorder: A clinical regression syndrome of increasing importance. Pediatrics, 145(6), e20192939. https://doi.org/10.1542/peds.2019-2939
  73. Sahu, P., Thippeswamy, H., & Chaturvedi, S. K. (2022). Neuropsychiatric manifestations in vitamin B12 deficiency. Vitamins and Hormones, 119, 457-470. https://doi.org/10.1016/bs.vh.2022.01.001
  74. Samsel, C., Brahmbhatt, K., Smith, J. R., et al. (2026). Recommendations for a pediatric catatonia clinical pathway in acute medical care settings: A Delphi consensus study. Journal of the Academy of Consultation-Liaison Psychiatry. https://doi.org/10.1016/j.jaclp.2026.03.007
  75. Santoro, J. D., Filipink, R. A., Baumer, N. T., Bulova, P. D., & Handen, B. L. (2023). Down syndrome regression disorder: Updates and therapeutic advances. Current Opinion in Psychiatry, 36(2), 96-103. https://doi.org/10.1097/YCO.0000000000000845
  76. Santoro, J. D., Jafarpour, S., Keehan, L., et al. (2024). Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder. Scientific Reports, 14(1), 30865. https://doi.org/10.1038/s41598-024-81819-8
  77. Santoro, J. D., Khoshnood, M. M., Nguyen, L., et al. (2025). Alternative diagnoses in the work up of Down syndrome regression disorder. Journal of Autism and Developmental Disorders, 55(6), 2085-2091. https://doi.org/10.1007/s10803-023-06057-9
  78. Santoro, J. D., Lee, S., Mlynash, M., et al. (2018). Blood pressure elevation and risk of moyamoya syndrome in patients with trisomy 21. Pediatrics, 142(4), e20180840. https://doi.org/10.1542/peds.2018-0840
  79. Santoro, J. D., Nguyen, L., Nishimori, N. A., et al. (2025). Safety and tolerability of home infusions in Down syndrome regression disorder. Clinical Therapeutics, 47(2), e27-e33. https://doi.org/10.1016/j.clinthera.2024.11.023
  80. Santoro, J. D., Patel, L., Kammeyer, R., et al. (2022). Assessment and diagnosis of Down syndrome regression disorder: International expert consensus. Frontiers in Neurology, 13, 940175. https://doi.org/10.3389/fneur.2022.940175
  81. Santoro, J. D., Silverman, M., Kazerooni, L., et al. (2026). Serum and cerebral folate are normal in Down syndrome regression disorder. Molecular Autism, 17(1), 9. https://doi.org/10.1186/s13229-026-00703-6
  82. Santoro, J. D., Silverman, M., Wang, A. C., et al. (2026). Delayed recognition and stroke-predominant presentation in Down syndrome-associated moyamoya syndrome. Stroke. https://doi.org/10.1161/STROKEAHA.126.056969
  83. Santoro, J. D., Spinazzi, N. A., Filipink, R. A., et al. (2023). Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Translational Psychiatry, 13(1), 276. https://doi.org/10.1038/s41398-023-02579-z
  84. Santoro, S. L., Cannon, S., Capone, G., et al. (2020). Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genetics in Medicine, 22(4), 767-776. https://doi.org/10.1038/s41436-019-0706-8
  85. Sargado, S., Milliken, A. L., Hojlo, M. A., et al. (2022). Is developmental regression in Down syndrome linked to life stressors? Journal of Developmental and Behavioral Pediatrics: JDBP, 43(7), 427-436. https://doi.org/10.1097/DBP.0000000000001086
  86. Seenivasan, A., Rachamim, E., & Santoro, J. D. (2025). A cross-sectional study survey to develop a clinical screen for Down syndrome regression disorder in the United Kingdom. American Journal of Medical Genetics Part A, e64207. https://doi.org/10.1002/ajmg.a.64207
  87. Sheehan, R., Horsfall, L., Strydom, A., et al. (2017). Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open, 7(8), e017406. https://doi.org/10.1136/bmjopen-2017-017406
  88. Shimizu, E., Goto-Hirano, K., Motoi, Y., Arai, M., & Hattori, N. (2024). Symptoms and age of prodromal Alzheimer's disease in Down syndrome: A systematic review and meta-analysis. Neurological Sciences, 45(6), 2445-2460. https://doi.org/10.1007/s10072-023-07292-9
  89. Shinomoto, M., Takeuchi, C., Tatebe, H., et al. (2024). Comparison between DSQIID total/sub-item scores and plasma p-tau elevation in adults with Down's syndrome. PLOS One, 19(12), e0311878. https://doi.org/10.1371/journal.pone.0311878
  90. Siegel, M., McGuire, K., Veenstra-VanderWeele, J., et al. (2020). Practice parameter for the assessment and treatment of psychiatric disorders in children and adolescents with intellectual disability (intellectual developmental disorder). Journal of the American Academy of Child and Adolescent Psychiatry, 59(4), 468-496. https://doi.org/10.1016/j.jaac.2019.11.018
  91. Silverman, W., Krinsky-McHale, S. J., Lai, F., et al. (2021). Evaluation of the National Task Group-Early Detection Screen for Dementia: Sensitivity to 'mild cognitive impairment' in adults with Down syndrome. Journal of Applied Research in Intellectual Disabilities: JARID, 34(3), 905-915. https://doi.org/10.1111/jar.12849
  92. Smith, J. R., Baldwin, I., Lim, S., & Luccarelli, J. (2024). Symptoms of catatonia observed in Down syndrome regressive disorder: A retrospective analysis. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-024-06249-x
  93. Smith, J. R., Hopkins, C. E., Xiong, J., et al. (2024). Use of ECT in autism spectrum disorder and/or intellectual disability: A single site retrospective analysis. Journal of Autism and Developmental Disorders, 54(3), 963-982. https://doi.org/10.1007/s10803-022-05868-6
  94. Sullivan, K. D., Evans, D., Pandey, A., et al. (2017). Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports, 7(1), 14818. https://doi.org/10.1038/s41598-017-13858-3
  95. Torr, J., & D'Abrera, J. C. (2014). Maintenance electroconvulsive therapy for depression with catatonia in a young woman with Down syndrome. The Journal of ECT, 30(4), 332-336. https://doi.org/10.1097/YCT.0000000000000116
  96. Totsika, V., Liew, A., Absoud, M., Adnams, C., & Emerson, E. (2022). Mental health problems in children with intellectual disability. The Lancet Child & Adolescent Health, 6(6), 432-444. https://doi.org/10.1016/S2352-4642(22)00067-0
  97. Tsou, A. Y., Bulova, P., Capone, G., et al. (2020). Medical care of adults with Down syndrome. JAMA, 324(15), 1543-1556. https://doi.org/10.1001/jama.2020.17024
  98. Ursumando, L., Fucà, E., Costanzo, F., & Vicari, S. (2022). Delusion of pregnancy in Down syndrome: Two case reports. International Journal of Environmental Research and Public Health, 19(20), 13339. https://doi.org/10.3390/ijerph192013339
  99. van Waarde, J. A., Stolker, J. J., & van der Mast, R. C. (2001). ECT in mental retardation: A review. The Journal of ECT, 17(4), 236-243. https://doi.org/10.1097/00124509-200112000-00002
  100. Walker, J. C., Dosen, A., Buitelaar, J. K., & Janzing, J. G. (2011). Depression in Down syndrome: A review of the literature. Research in Developmental Disabilities, 32(5), 1432-1440. https://doi.org/10.1016/j.ridd.2011.02.010
  101. Wang, S., Patel, L., Sannar, E. A., et al. (2023). Adverse childhood experiences and the development of Down syndrome regression disorder. American Journal of Medical Genetics Part A, 191(7), 1769-1782. https://doi.org/10.1002/ajmg.a.63199
  102. Waugh, K. A., Minter, R., Baxter, J., et al. (2023). Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nature Genetics, 55(6), 1034-1047. https://doi.org/10.1038/s41588-023-01399-7
  103. Wijdicks, E. F. M., & Ropper, A. H. (2024). Neuroleptic malignant syndrome. The New England Journal of Medicine, 391(12), 1130-1138. https://doi.org/10.1056/NEJMra2404606
  104. Wilson, J. E., Carlson, R., Duggan, M. C., et al. (2017). Delirium and catatonia in critically ill patients: The delirium and catatonia prospective cohort investigation. Critical Care Medicine, 45(11), 1837-1844. https://doi.org/10.1097/CCM.0000000000002642
  105. Wilson, J. E., Oldham, M. A., Francis, A., et al. (2025). Resource document on catatonia. American Psychiatric Association.
  106. Wisch, J. K., Jiao, Z., Kennedy, J. T., et al. (2026). Imaging and plasma biomarkers for pathological accumulation in Down syndrome. Brain: A Journal of Neurology, 149(6), 1944-1957. https://doi.org/10.1093/brain/awaf418
  107. Worley, G., Crissman, B. G., Cadogan, E., et al. (2015). Down syndrome disintegrative disorder: New-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. Journal of Child Neurology, 30(9), 1147-1152. https://doi.org/10.1177/0883073814554654
  108. Zalzal, H. G., & Lawlor, C. M. (2023). Down syndrome for the otolaryngologist. JAMA Otolaryngology--Head & Neck Surgery, 149(4), 360-367. https://doi.org/10.1001/jamaoto.2023.0001
  109. Zhou, J. Y., Xu, B., Lopes, J., Blamoun, J., & Li, L. (2017). Hashimoto encephalopathy: Literature review. Acta Neurologica Scandinavica, 135(3), 285-290. https://doi.org/10.1111/ane.12618